Introduction {#S1}
============

Cardiovascular autonomic neuropathy (CAN) is one of the most serious diabetic complications but is often unrecognized by patients and clinicians ([@B29]; [@B4]). Varying incidence and prevalence of CAN are reported in different studies among diabetic patients with the rates ranging from as low as 1.6% in patients with well-controlled diabetes to as high as 90% in those awaiting a pancreas transplant ([@B28]).

Dysfunctions of the autonomic nervous system among CAN patients result in impaired cardiovascular regulation ([@B3]). Consequently, diabetic patients with undiagnosed CAN have increased cardiovascular risks that can be suddenly fatal ([@B12]).

The development of CAN is reported to be associated with poor glycemic control, duration of diabetes, old age, female gender, and lifestyle factors such as smoking ([@B16]; [@B21]). However, there is wide heterogeneity in the causes and progression of CAN among diabetics ([@B21]).

Assessing patients for the presence of CAN is generally based on stimulating autonomic physiological functions and observing end-organ reactions. The tests include evaluating heart rate variations (HRV) and blood pressure changes ([@B15]). Some of the techniques employed in assessing HRV are deep-breathing (DB), lying-to-standing (LS), and Valsalva (V) maneuvers; these reflect parasympathetic function. On the other hand, measuring blood pressure changes during orthostatis, Valsalva (V) maneuvers and sustained isometric muscular strain aid in evaluating sympathetic function ([@B10]). There is no specific algorithm for detecting CAN but, for proper diagnosis of the condition, it is recommended that more than one test is conducted to improve the sensitivity and reliability of the detection ([@B20]; [@B22]; [@B8]). The present study was undertaken with the aim of evaluating the prevalence of CAN among diabetic patients in Beijing, China. A further purpose of the study was to evaluate the specificity and sensitivity of the various functional tests in the assessment of CAN.

Materials and Methods {#S2}
=====================

Subjects {#S2.SS1}
--------

Data of diabetic patients undergoing cardiac autonomic neuropathy assessment was collected retrospectively from 13 hospitals in Beijing. From each hospital 160 cases were randomly sampled over a period of 12 weeks. A randomly selected day every week was used as a day of investigation. The inclusion criteria for the study were as follows: (1) Meeting T1DM or T2DM diagnosis standards established by the [@B33]. (2) Patient maintaining appropriate attention throughout the study. (3) Ability to understand study instructions and cooperate in completing the assessment. The exclusion criteria were: (1) Existence of other causes of neuropathy such as cervical lumbar lesions, cerebral infarction, and Guillain-Barre syndrome. (2) Patients who had serious arteriovenous vascular lesions. (3) Patients with neurotoxic effects caused by drugs in the setting of renal insufficiency. (4) Patients who were taking beta-blocker drugs. (5) Pregnant or breast-feeding women. (6) Patients with mental illness. (7) Patients who were reluctant to cooperate with study instructions. The study was approved by the institutional review boards at each study site and informed consent was obtained from all participants.

CAN Evaluation {#S2.SS2}
--------------

Sympathetic and parasympathetic function tests were performed to provide preliminary diagnosis of CAN. Standardized CAN evaluation was conducted by four non-invasive cardiovascular autonomic function tests as previously described ([@B17]; [@B19]). In our study, a diagnosis of CAN was confirmed based on abnormal results in any two of the four tests described hereafter.

### Deep-Breathing (DB) Test {#S2.SS2.SSS1}

Following 20-min acclimatization, the patient was asked to sit calmly and take 6 breaths, deeply and discreetly, over a period of 1 min. An electrocardiogram (ECG) reading was taken throughout this period. Additionally, the maximum and minimum beat-to-beat (R-R) intervals were recorded and beats per minute were derived from this value. The induced heart rate change was determined by calculating the mean of the difference between minimum and maximum heart rates during 6 rounds of the DB test. A difference of ≥15 beats/min was considered normal; 11--14 beats/min was taken to be borderline while a value of ≤10 beats/min was considered abnormal.

### Lying-to-Standing (LS) Test {#S2.SS2.SSS2}

The patient was requested to lie in a supine position and an ECG recording was taken. Thereafter, the patient was asked to stand up. The maximum R-R interval close to the 15th beat and the minimum R-R interval close to the 30th beat was obtained. From these, the R-R ratio at the 30th and 15th beats (30/15 ratio) was calculated. A ratio ≥1.04 was considered normal; 1.01--1.03 was identified as borderline, and ≤1.00 was considered abnormal.

### Valsalva (V) Tests {#S2.SS2.SSS3}

The patient was asked to sit in a relaxed state and blow hard to make the mercury sphygmomanometer rise to 40 mmHg for 15s before releasing pressure while an ECG reading was being taken. Differences in the heart rate evoked by the Valsalva maneuver were measured as the ratio of the highest tachycardia during the maneuver to the lowest bradycardia after the maneuver. This Valsalva ratio was presented as the ratio of maximum R-R interval after the Valsalva maneuver to minimum R-R interval during the Valsalva maneuver. A ratio of ≥1.21 was considered normal; 1.11--1.20 was taken to be borderline, and ≤1.10 was considered abnormal.

### Change in SBP in Response to Lying-to-Standing Positions {#S2.SS2.SSS4}

The patient was asked to lie calmly in a supine position and then to stand up while blood pressure was monitored. A drop in SBP by ≤10 mmHg in response to standing was considered normal, whereas a fall in SBP of ≥30 mmHg was taken to be abnormal.

Statistical Analysis {#S2.SS3}
--------------------

Continuous data with a normal distribution were displayed as means and standard deviations and compared using the independent *t*-test. Continuous data with a skewed distribution were displayed as medians and interquartile ranges and compared using the Wilcoxon rank-sum test. Categorical data were presented as frequencies or percentages and compared using the chi-square test. Clinical characteristics were compared between those with and without CAN. Multivariate logistic regression analysis was performed to estimate the risk factors for developing CAN. The risk factors that differed significantly between the CAN and the non-CAN patients were included in the model. In addition, age and gender were also entered into the model as adjustment variables. The receiver operating characteristic curve was then used to evaluate the performance of the 4 tests both in isolation and their respective combinations in the diagnosis of CAN to determine the optimal diagnostic method ([@B7]). A value of *P* \< 0.05 was considered statistically significant. The SAS software version 9.2 was utilized for all analyses.

Results {#S3}
=======

The study recruited 2,048 subjects that were categorized into T1DM (*n* = 73) and T2DM (*n* = 1975) groups. The general characteristics of the two groups with respect to their CAN status are presented in [Table 1](#T1){ref-type="table"}. The prevalence of CAN in T1DM and T2DM was 61.6% and 62.6%, respectively. In contrast to T1DM patients, CAN patients suffering from T2DM had significant differences (*P* \< 0.01), in comparison to patients without CAN, in terms of age, education, childbearing history and medical payment.

###### 

General characteristics of T1DM and T2DM patients by CAN status.

                                   **T1DM**        **T2DM**                                                                   
  -------------------------------- --------------- --------------- --------- ------- --------------- --------------- -------- --------------
  Gender                                                                                                                      
  Male, *n* (%)                    24 (53.33)      15 (53.57)      \<0.001   0.984   604 (48.87)     389 (52.64)     2.631    0.105
  Female, *n* (%)                  21 (46.67)      13 (46.43)                        632 (51.13)     350 (47.36)              
  Age, year                        52.96 ± 13.30   54.57 ± 12.98   −0.509    0.612   60.20 ± 10.63   57.14 ± 10.97   −6.116   \<0.001^∗∗∗^
  \<60 years, *n* (%)              25 (55.56)      13 (46.43)      0.576     0.448   548 (44.34)     408 (55.21)     21.893   \<0.001^∗∗∗^
  ≥60 years, *n* (%)               20 (44.44)      15 (53.57)                        688 (55.66)     331 (44.79)              
  BMI                                                                                                                         
  \<24, *n* (%)                    19 (42.22)      10 (35.71)      1.459     0.482   413 (33.41)     249 (33.69)     0.783    0.676
  24--27.99, *n* (%)               18 (40.00)      15 (53.57)                        557 (45.06)     343 (46.41)              
  ≥28, *n* (%)                     8 (17.78)       3 (10.71)                         266 (21.52)     147 (19.89)              
  Education, *n* (%)                                                                                                          
  Middle school or below           20 (44.44)      8 (28.57)       2.401     0.301   545 (44.09)     243 (32.88)     24.724   \<0.001^∗∗∗^
  High school                      14 (31.11)      9 (32.14)                         344 (27.83)     237 (32.07)              
  Colleges and universities        11 (24.44)      11 (39.29)                        347 (28.07)     259 (35.05)              
  Child-bearing history, *n* (%)                                                                                              
  0                                5 (11.11)       3 (10.71)       0.059     0.971   71 (5.74)       50 (6.77)       7.866    0.020^∗^
  1                                22 (48.89)      13 (46.43)                        713 (57.69)     464 (62.79)              
  ≥2                               18 (40.00)      12 (42.86)                        452 (36.57)     225 (30.45)              

Data are mean ± SD or n (%),

P

value is calculated by the Wilcoxon rank sum test or the χ2 test comparing CAN vs. non-CAN.

∗

P

\< 0.05;

∗∗∗

P

\< 0.001.

As shown in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, there were observable differences in patient characteristics and medication history between the cohorts. Parameters correlating with CAN among T1DM include longer duration disease (*z* = 2.131, *P* = 0.033) and longer metformin medication use (*z* = 3.059, *P* = 0.002). On the other hand, among T2DM patients, correlation with CAN was seen with longer duration of disease (*z* = −4.204, *P* \< 0.001), higher hypoglycemic level (*z* = −2.200, *P* = 0.028), larger metformin dosage (*z* = −2.858, *P* = 0.004) and longer metformin medication time (*z* = −4.364, *P* \< 0.001).

###### 

Patient history and complications of T1DM and T2DM groups by CAN status.

                                                **T1DM**         **T2DM**                                                                              
  --------------------------------------------- ---------------- ------------------ --------- ----------- ----------------- ---------------- --------- ------------------
  Course of disease, year, median (IQR)         12 (3--17)       5 (3--11)          2.131     0.033^∗^    10 (4--15)        7.5 (3--12)      --4.204   \< 0.001^\*\*\*^
  \<5 years, *n* (%)                            13 (28.89)       10 (35.71)         6.952     0.031^∗^    351 (28.40)       247 (33.42)      15.277    \< 0.001^\*\*\*^
  5--10 years, *n* (%)                          5 (11.11)        9 (32.14)                                241 (19.50)       174 (23.55)                
  ≥10 years, *n* (%)                            27 (60.00)       9 (32.14)                                644 (52.10)       318 (43.03)                
  HbA1c, median (IQR)                           8 (7--9.4)       7.3 (6.5--8.3)     1.612     0.107       7.6 (6.7--8.99)   7.3 (6.5--8.6)   --2.200   0.028^∗^
  Hypoglycemia                                                                                                                                         
  Yes, *n* (%)                                  16 (35.56)       7 (25.00)          0.891     0.345       188 (25.44)       328 (26.54)      0.289     0.591
  No, *n* (%)                                   29 (64.44)       21 (75.00)                               551 (74.56)       908 (73.46)                
  Metformin                                                                                                                                            
  Yes, *n* (%)                                  25 (55.56)       15 (53.57)         0.027     0.868       434 (58.73)       755 (61.08)      1.072     0.301
  No, *n* (%)                                   20 (44.44)       13 (46.43)                               305 (41.27)       481 (38.92)                
  Metformin dosage in g, median (IQR)           1.5 (1.5--1.5)   1.5 (0.125--1.5)   1.681     0.093       1.5 (1--2)        1.5 (0.5--1.5)   --2.858   0.004^∗∗^
  Duration of medication, month, median (IQR)   96 (30--161)     16 (1--66)         3.059     0.002^∗∗^   48 (8--120)       24 (1--96)       --4.364   \< 0.001^\*\*\*^
  Kidney disease                                                                                                                                       
  Yes, *n* (%)                                  9 (20.00)        0 (0.00)           6.388     0.011^∗^    107 (8.66)        48 (6.50)        2.988     0.084
  No, *n* (%)                                   36 (80.00)       28 (100.00)                              1129 (91.34)      691 (93.50)                
  Retinopathy                                                                                                                                          
  Yes, *n* (%)                                  11 (24.44)       0 (0.00)           8.059     0.005^∗∗^   274 (22.20)       137 (18.56)      3.710     0.054
  No, *n* (%)                                   34 (75.56)       28 (100.00)                              960 (77.80)       601 (81.44)                
  Coronary heart disease                                                                                                                               
  Yes, *n* (%)                                  2 (4.44)         0 (0.00)           1.280     0.258       211 (17.14)       90 (12.23)       8.576     0.003^∗∗^
  No, *n* (%)                                   43 (95.56)       28 (100.00)                              1020 (82.86)      646 (87.77)                
  Cerebral infarction                                                                                                                                  
  Yes, *n* (%)                                  1 (2.22)         0 (0.00)           0.631     0.427       135 (10.99)       69 (9.35)        1.340     0.247
  No, *n* (%)                                   44 (97.78)       28 (100.00)                              1093 (89.01)      669 (90.65)                
  Diabetic neuropathy                                                                                                                                  
  Yes, *n* (%)                                  8 (17.78)        5 (17.86)          \<0.001   0.993       153 (12.40)       93 (12.58)       0.015     0.904
  No, *n* (%)                                   37 (82.22)       23 (82.14)                               1081 (87.6)       646 (87.42)                

Data are medians and interquartile ranges or n (%),

P

value is calculated by the Wilcoxon rank sum test or the χ2 test comparing CAN vs. non-CAN.

∗

P

\< 0.05;

∗∗

P

\< 0.01;

∗∗∗

P

\< 0.001. IQR, interquartile range.

###### 

Symptoms of T1DM and T2DM groups by CAN status.

                               **T1DM**      **T2DM**                                                                
  ---------------------------- ------------- ------------- ------- ---------- -------------- ------------- --------- --------------
  **Tumble**                                                                                                         
  Yes, *n* (%)                 0 (0.00)      0 (0.00)      --      --         80 (6.53)      38 (5.15)     1.556     0.212
  No, *n* (%)                  45 (100.00)   28 (100.00)                      1145 (93.47)   700 (94.85)             
  **Dizziness, instability**                                                                                         
  Yes, *n* (%)                 13 (100.00)   3 (60.00)     5.850   0.016^∗^   317 (66.74)    157 (55.48)   9.600     0.002^∗∗^
  No, *n* (%)                  0 (0.00)      2 (40.00)                        158 (33.26)    126 (44.52)             
  **Dyspnea**                                                                                                        
  Yes, *n* (%)                 0 (0.00)      0 (0.00)      --      --         44 (21.67)     22 (14.86)    2.600     0.107
  No, *n* (%)                  0 (0.00)      2 (100.00)                       159 (78.33)    126 (85.14)             
  **Weak**                                                                                                           
  Yes, *n* (%)                 13 (100.00)   9 (81.82)     2.579   0.108      355 (69.07)    192 (60.38)   6.586     0.010^∗^
  No, *n* (%)                  0 (0.00)      2 (18.18)                        159 (30.93)    126 (39.62)             
  **Coma**                                                                                                           
  Yes, *n* (%)                 0 (0.00)      0 (0.00)      --      --         5 (3.05)       4 (3.08)      \<0.001   0.989
  No, *n* (%)                  0 (0.00)      2 (100.00)                       159 (96.95)    126 (96.92)             
  **Postprandial fullness**                                                                                          
  Yes, *n* (%)                 6 (85.71)     1 (33.33)     2.744   0.098      192 (44.92)    107 (36.9)    4.625     0.032^∗^
  No, *n* (%)                  1 (14.29)     2 (66.67)                        235 (55.04)    183 (63.10)             
  **Nausea**                                                                                                         
  Yes, *n* (%)                 4 (80.00)     1 (33.33)     1.742   0.187      70 (22.95)     40 (17.94)    1.963     0.161
  No, *n* (%)                  1 (20.00)     2 (66.67)                        235 (77.05)    183 (82.06)             
  **Emesis**                                                                                                         
  Yes, *n* (%)                 1 (50.00)     0 (0.00)      1.333   0.248      22 (8.56)      16 (8.04)     0.040     0.842
  No, *n* (%)                  1 (50.00)     2 (100.00)                       235 (91.44)    183 (91.96)             
  **Epigastric pain**                                                                                                
  Yes, *n* (%)                 0 (0.00)      2 (50.00)     0.833   0.361      23 (8.91)      17 (8.50)     0.024     0.876
  No, *n* (%)                  1 (100.00)    2 (50.00)                        235 (91.09)    183 (91.50)             
  **Dysuria**                                                                                                        
  Yes, *n* (%)                 0 (0.00)      0 (0.00)      --      --         73 (28.63)     43 (21.94)    2.595     0.107
  No, *n* (%)                  1 (100.00)    2 (100.00)                       182 (71.37)    153 (78.06)             
  **Frequent urination**                                                                                             
  Yes, *n* (%)                 8 (88.89)     6 (75.00)     0.562   0.453      253 (58.16)    113 (42.48)   16.265    \<0.001^∗∗∗^
  No, *n* (%)                  1 (11.11)     2 (25.00)                        182 (41.84)    153 (57.52)             
  **Nocturia**                                                                                                       
  Yes, *n* (%)                 14 (93.33)    10 (83.33)    0.675   0.411      209 (53.45)    96 (38.55)    13.536    \<0.001^∗∗∗^
  No, *n* (%)                  1 (6.67)      2 (16.67)                        182 (46.55)    153 (61.45)             
  **Urgent urination**                                                                                               
  Yes, *n* (%)                 3 (75.00)     4 (66.67)     0.079   0.778      140 (43.61)    59 (27.83)    13.595    \<0.001^∗∗∗^
  No, *n* (%)                  1 (25.00)     2 (33.33)                        181 (56.39)    153 (72.17)             
  **Sexual function**                                                                                                
  Satisfaction, *n* (%)        2 (66.67)     2 (66.67)     --      --         62 (24.41)     42 (22.34)    0.257     0.612
  Dissatisfaction, *n* (%)     1 (33.33)     1 (33.33)                        192 (75.59)    146 (77.66)             
  **Upper body sweating**                                                                                            
  Yes, *n* (%)                 13 (100.00)   4 (80.00)     2.753   0.097      250 (56.56)    127 (46.52)   6.826     0.009^∗∗^
  No, *n* (%)                  0 (0.00)      1 (20.00)                        192 (43.44)    146 (53.48)             
  **Head and neck sweating**                                                                                         
  Yes, *n* (%)                 2 (100.00)    3 (75.00)     0.600   0.439      98 (33.79)     52 (26.26)    3.134     0.077
  No, *n* (%)                  0 (0.00)      1 (25.00)                        192 (66.21)    146 (73.74)             

Data are

n

(%),

P

value is calculated using the χ

2

test comparing CAN vs. non-CAN.

∗

P

\< 0.05;

∗∗

P

\< 0.01;

∗∗∗

P

\< 0.001.

With reference to disease symptoms and complications, kidney disease (χ^2^ = 6.388, *P* = 0.011), retinopathy (χ^2^ = 8.059, *P* = 0.005), dizziness and instability (χ^2^ = 5.85, *P* = 0.016) were the most correlated with CAN among T1DM patients. In comparison, among T2DM patients, CAN was associated with coronary heart disease (χ^2^ = 8.576, *P* = 0.003), peripheral vascular disease (χ^2^ = 5.759, *P* = 0.016) and dizziness, instability (χ^2^ = 9.600, *P* = 0.002). Other symptoms were weakness (χ^2^ = 6.586, *P* = 0.010), postprandial fullness (χ^2^ = 4.625, *P* = 0.032), frequent urination (χ^2=^16.265, *P* \< 0.001), nocturia (χ^2^ = 13.536, *P* ≤ 0.001), urgent urination (χ^2^ = 13.595, *P* \< 0.001) and upper body sweating (χ^2^ = 6.826, *P* = 0.009).

Considering both T1DM and T2DM groups, the most frequent symptoms of CAN were weakness (28.6%), dizziness (23.4%), frequent urination (19.6%), upper body sweating (18.4%), and nocturia (15.9%). The specificity of all the above symptoms was poor since they may occur in other diseases, thus necessitating further screening.

In view of the past medical history of diabetic patients, we found that the proportion of CAN patients with hypertension was higher than that in non-CAN patients in T2DM (χ^2^ = 11.886, *P* = 0.001). Interestingly, the serum levels of triglycerides (TG) of CAN patients were lower than that in non-CAN patients (χ^2^ = 2.273, *P* = 0.023).

To evaluate the relative contribution of individual risk factors for CAN in both patient cohorts, we performed regression analysis. In T1DM, duration of disease was an independent risk factor for developing CAN (OR = 1.122, 95% CI 1.026--1.228, *P* = 0.011) ([Table 4](#T4){ref-type="table"}) whereas in T2DM, age was an independent risk factor (OR = 1.040, 95% CI 1.008--1.072, *P* = 0.012) ([Table 5](#T5){ref-type="table"}).

###### 

Risk factors for CAN in TIDM patients.

                               **OR**   **95% CI lower**   **95% CI upper**   ***P***
  ---------------------------- -------- ------------------ ------------------ ---------
  Gender                       1.610    0.536              4.837              0.396
  Age                          0.966    0.924              1.009              0.123
  Duration of disease (year)   1.122    1.026              1.228              0.011
  Hba1c                        1.151    0.845              1.566              0.372

A value of

P

\< 0.05 was considered to be statistically significant.

###### 

Risk factors for CAN in T2DM patients.

                                **OR**   **95% CI lower**   **95% CI upper**   ***P***
  ----------------------------- -------- ------------------ ------------------ ---------
  Gender                        0.756    0.461              1.240              0.268
  Age                           1.040    1.008              1.072              0.012
  Education                     0.974    0.716              1.323              0.864
  Course of disease             1.007    0.974              1.042              0.680
  Hba1c                         1.063    0.915              1.235              0.424
  Use of metformin              0.710    0.318              1.586              0.403
  Metformin dosage              0.964    0.669              1.390              0.845
  Nephropathy                   0.704    0.288              0.717              0.440
  Retinopathy                   0.907    0.499              1.648              0.747
  Coronary heart disease        1.375    0.729              2.595              0.326
  Peripheral vascular disease   0.464    0.214              1.007              0.052
  Dizziness, instability        0.977    0.534              1.788              0.941
  Fullness                      0.924    0.474              1.799              0.816
  Hypertension                  0.668    0.407              1.096              0.110
  TG                            0.978    0.831              1.152              0.793
                                                                               

The four diagnostics tests were evaluated individually and in combination to find the optimal test (or test combinations) for CAN among the sampled Chinese diabetic patients. For the T1DM group, the optimal CAN diagnostic approach was combining the V and LS tests (sensitivity = 97.6%, AUC = 0.887) ([Figures 1A,C](#F1){ref-type="fig"}); while for the T2DM group, the DB test had the highest sensitivity (83.6%) and a combination of V and DB tests gave the maximal AUC (0.856) ([Figures 1B,C](#F1){ref-type="fig"}).

![Cardiovascular autonomic neuropathy (CAN) diagnostic tests in **(A)** T1DM, **(B)** T2DM, and **(C)** combination of CAN diagnosis tests in T1DM and T2DM.](fnins-13-01144-g001){#F1}

Discussion {#S4}
==========

Many diabetic patients suffer from CAN without knowing it until, at times, the condition has progressed to late stage. Previous studies provide data about CAN prevalence in diabetic patients, mostly among Western populations ([@B36]). Few such studies have been conducted among the Chinese, hence the motivation for the present study.

The prevalence of CAN as found in this study is 63%. This observation corroborates what was reported by [@B5], [@B26], [@B35]. Furthermore, risk factors associated with CAN were the duration of disease and age, respectively, in T1DM and T2DM participants. This observation corroborates that reported by other researchers ([@B27]; [@B34]).

Patients taking beta-blocker drugs, which could have impacted on the outcomes of autonomic function tests, were excluded from the study. This explains the comparable low rate of coronary heart disease among CAN as opposed to non-CAN patients with T1DM. Similarly, the levels of TGs among patients with CAN was lower compared to those among the non-CAN patients.

Typical diagnosis of CAN relies on finding 2 or more abnormal results of autonomic function tests ([@B11]). We followed a similar approach and, to reduce bias, all tests were executed in the same room, by the same person and applying the same instruments and devices for the duration of the study.

Results from this study demonstrate that the occurrence of CAN among patients with diabetes is related to the duration of disease and the age of the patient. A correlation with the use of Metformin, HbA1c level, neuropathy, retinopathy, coronary heart disease, peripheral vascular disease, hypertension and TG level, although reported in previous studies ([@B32]), was not evident. This shows how complex and heterogeneous the cause and progression of CAN is.

Regression analysis showed that the HbA1c level was not an independent risk factor for both T1DM and T2DM patients. The HbA1c level was estimated during the first CAN screening and can only represent the blood glucose control over the past 3 months. Additionally, it is possible that glycemic variability may induce hypoglycemic stress leading to decreased HRV independent of glycemic control as estimated by HbA1c ([@B14]).

Our study found that nearly 20% of T1DM patients with CAN also suffered from kidney disease. The connection between CAN and kidney disease in diabetic patients is rather complicated. Some reports demonstrate that CAN accelerates the progress of kidney disease in T1DM patients ([@B31]; [@B2]). As reported also previously ([@B25]), we found kidney disease to be an independent risk factor for the prevalence of CAN in T2DM. In contrast, a large prospective observational study in which 388 T1DM cases were followed-up for 10 years did not find an association between CAN and kidney disease ([@B1]). In supporting the relationship between CAN and kidney disease, the former has been shown to affect the glomerular filtration pressure, glomerular endothelial cell damage and erythropoietin secretion ([@B24]; [@B6]; [@B13]).

This study found that for T1DM, the optimal CAN diagnostic method is the use of the V test in combination with the LS test while for T2DM, the DB test had the highest sensitivity with combined V and DB tests giving the maximal AUC. Since the initial method described by Ewing et al. in distinguishing CAN from non-CAN among diabetic patients ([@B9]), efforts aimed at simplifying CAN diagnosis have been explored. For example, [@B18] showed that the Ewing tests could be simplified with the same test efficiency by reducing the number of tests to three: the Valsalva maneuver, deep breathing (DB), and isometric handgrip tests. Later, [@B23] found out that the DB test was the optimal single test for CAN diagnosis, while adding some of the remaining tests could obtain additional accuracy.

From this study, we have therefore obtained insights into the prevalence of CAN and found the optimal methods for CAN diagnosis in the respective groups of diabetic patients. The study, however, is not without limitations. First, there is great discrepancy between the number of T1DM and T2DM patients, making direct comparisons of characteristics and observations between the two patient groups difficult. Moreover, we did not categorize the CAN cases according to the level of severity since our aim was to optimize the tests for CAN diagnosis and not to stage the condition. Besides, most of the patients included in our study were in their fifth and sixth decades of life, and hence, had long duration of diabetes. For this reason, the results obtained in this study may not be reflective of the general population of diabetic patients. Further studies involving a wider age spectrum, including younger patients, are required to further validate and verify our findings.

Conclusion {#S5}
==========

The current study found the prevalence of diabetic patients suffering from CAN to be 63%. Further regression analysis demonstrated that the course of disease and age are independent risk factors of CAN in T1DM and T2DM, respectively. Moreover, a combination of V test and LS test was found to be optimal for CAN diagnosis in T1DM while in T2DM, combining the V and DB tests gave the best results. Larger prospective studies with longer follow-up periods are recommended to confirm these results.
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